Nav: Home

P38 alpha: The switch controlling obesity and diabetes

July 18, 2018

One of the research lines targeting the worldwide obesity epidemic is the manipulation of brown fat, a 'good' type of fat tissue that burns lipids to maintain an appropriate body temperature. Researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) have now uncovered the mechanism by which brown fat cells are activated to generate heat and eliminate excess fat. The results, published in PLoS Biology, have potential clinical implications for the treatment of obesity and related diseases like diabetes.

Obesity is a global epidemic, with an estimated 2200 million people affected by excess weight or obesity. This situation has converted obesity into a priority concern of the World Health Association (WHO).

In recent years, research interest has centered on understanding the function of adipose tissue, particularly brown adipose tissue, as a route to tackling the problems caused by obesity. Body fat is essential for maintaining a correct energy balance and for regulating body temperature. But not all fat tissue is the same, and there are two types of adipose tissue: white adipose tissue that stores excess calories, and brown adipose tissue--a 'good' fat that burns fats to generate heat. Overturning the old view that fat has no essential function, research in recent years indicates that activation of brown adipose tissue could be the solution to the problem of obesity.

The research group led by Dr. Guadalupe Sabio has been pursuing a promising research line aimed at understanding how brown adipose tissue can be activated in order to burn the excess fat that accumulates in obese individuals. In collaboration with the Instituto de Investigación Biomédica de Salamanca (IBSAL) and Salamanca University Hospital, this CNIC group has identified a new mechanism with future clinical implications. In more than 150 human samples, the researchers have demonstrated that the protein kinase p38 alpha is more abundant in the adipose tissue of obese individuals. According to researcher Nuria Matesanz, the finding suggests that "p38 alpha may regulate UCP1, an important protein for brown fat activation that dissipates the energy generated from burning excess fat as heat."

In experiments with mice genetically modified to lack p38 alpha, the research team found that the absence of this protein in adipose tissue prevents the mice from becoming obese even when fed a high-fat diet. This protection, explains research team member Ivana Nikolic, "is due to the fact that the lack of p38 alpha activates brown adipose tissue, which eliminates excess white fat in the form of heat." Just as important, the study shows that mice lacking p38 alpha are protected against diabetes and fatty liver disease.

For lead autor Dr. Sabio, these results are very promising, as they "suggest that pharmacological inhibition of p38 alpha could offer a route to the treatment of obesity."

The study also reveals another important finding: p38 alpha controls the activation of another protein of the same family, p38 delta, which is responsible for temperature regulation. As the authors explain, "When mice are exposed to low temperatures, p38 delta is activated, increasing the activity of brown fat." In mice lacking p38, p38 delta is overactivated, resulting in protection against obesity.
-end-
The study was possible thanks to collaborations with researchers at the Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS) at the University of Extremadura and the Instituto de Investigación en Biomedicina (IRB) in Barcelona. The study findings could provide the basis for research to find therapeutic targets to combat obesity.

About the CNIC


The Centro Nacional de Investigaciones Cardiovasculares (CNIC), directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 14 of the most important Spanish private companies.

Centro Nacional de Investigaciones Cardiovasculares

Related Diabetes Articles:

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.